Investor Relations

Latest Financial Results

FY 2016

Fiscal Year Ended Dec 31, 2016

Stock Information

Aurinia Pharmaceuticals Inc.
Day Range
52 Wk Range

Company Overview

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. The Company is headquartered in Victoria, BC and focuses its development efforts globally.

view management team  view board of directors

Contact Information

Investor Relations

Celia Economides
Associate VP, IR, Communications & Advocacy
T: +1-250-744-2487

Transfer Agent

Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
T: +1-514-982-7555